N Tahani1,2, L Nieddu3, G Prossomariti4, M Spaziani5,6, S Granato5,6, F Carlomagno5,6, A Anzuini6, A Lenzi6, A F Radicioni5,6, E Romagnoli6. 1. Centre for Rare Diseases, Policlinico Umberto I, Rome, Italy. natascia.tahani@uniroma1.it. 2. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy. natascia.tahani@uniroma1.it. 3. Faculty of Economics, UNINT University for International Studies of Rome, Rome, Italy. 4. Department of Radiology, Sapienza University of Rome, Rome, Italy. 5. Centre for Rare Diseases, Policlinico Umberto I, Rome, Italy. 6. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
Abstract
PURPOSE: To assess different aspects of bone damage in untreated adult patients with Klinefelter Syndrome (KS) before and during testosterone replacement therapy (TRT). METHODS: Fifteen untreated hypogonadal men with KS and 26 control subjects (C) matched for age and BMI were recruited. Sex hormone levels were measured in all subjects. Lumbar spine (LS) and femoral (neck: FN and total hip: TH) bone mineral density (BMD), trabecular bone score (TBS), hip structure analysis (HSA) and fat measures (percentage of fat mass, android/gynoid ratio and visceral adipose tissue) were evaluated by DEXA. In KS patients, blood analysis and DEXA measurements were assessed at baseline and repeated yearly for three years during TRT. RESULTS: Fat measures were significantly higher in KS than C (p < 0.01). In contrast, mean LS, FN and TH BMD were significantly reduced in KS compared to C (p < 0.01), while there was no difference in TBS. HSA revealed a significantly lower cortical thickness and significantly higher buckling ratio in KS compared to C at all femoral sites (p < 0.01). In KS patients, TRT significantly increased BMD at LS only, but did not improve TBS and HSA parameters. Fat measures were inversely associated with TBS values, and TRT did not influence this relationship. CONCLUSIONS: In untreated hypogonadal men with KS, lumbar and femoral BMD was reduced, and femoral bone quality was impaired. Adiposity seemed to have a detrimental effect on lumbar bone microarchitecture, as indirectly evaluated by TBS. However, TRT failed to remedy these negative effects on bone.
PURPOSE: To assess different aspects of bone damage in untreated adult patients with Klinefelter Syndrome (KS) before and during testosterone replacement therapy (TRT). METHODS: Fifteen untreated hypogonadal men with KS and 26 control subjects (C) matched for age and BMI were recruited. Sex hormone levels were measured in all subjects. Lumbar spine (LS) and femoral (neck: FN and total hip: TH) bone mineral density (BMD), trabecular bone score (TBS), hip structure analysis (HSA) and fat measures (percentage of fat mass, android/gynoid ratio and visceral adipose tissue) were evaluated by DEXA. In KS patients, blood analysis and DEXA measurements were assessed at baseline and repeated yearly for three years during TRT. RESULTS: Fat measures were significantly higher in KS than C (p < 0.01). In contrast, mean LS, FN and TH BMD were significantly reduced in KS compared to C (p < 0.01), while there was no difference in TBS. HSA revealed a significantly lower cortical thickness and significantly higher buckling ratio in KS compared to C at all femoral sites (p < 0.01). In KS patients, TRT significantly increased BMD at LS only, but did not improve TBS and HSA parameters. Fat measures were inversely associated with TBS values, and TRT did not influence this relationship. CONCLUSIONS: In untreated hypogonadal men with KS, lumbar and femoral BMD was reduced, and femoral bone quality was impaired. Adiposity seemed to have a detrimental effect on lumbar bone microarchitecture, as indirectly evaluated by TBS. However, TRT failed to remedy these negative effects on bone.
Entities:
Keywords:
Bone mineral density; Hip structural analysis; Klinefelter syndrome; Trabecular bone score
Authors: W Vena; F Carrone; G Mazziotti; A Ferlin; A Delbarba; O Akpojiyovbi; L C Pezzaioli; P Facondo; C Cappelli; L Leonardi; L Balzarini; D Farina; A Pizzocaro; A G Lania Journal: J Endocrinol Invest Date: 2022-08-28 Impact factor: 5.467
Authors: M Spaziani; S Granato; N Liberati; F M Rossi; N Tahani; C Pozza; D Gianfrilli; G Papi; A Anzuini; A Lenzi; L Tarani; A F Radicioni Journal: J Endocrinol Invest Date: 2020-05-06 Impact factor: 4.256
Authors: Milou Cecilia Madsen; Martin den Heijer; Claudia Pees; Nienke R Biermasz; Leontine E H Bakker Journal: Endocr Connect Date: 2022-07-25 Impact factor: 3.221